Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Rating of "Hold" from Analysts

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has been given an average rating of "Hold" by the twenty-one research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $137.55.

• GRAIL: Biotech Stock Targeting $100B Cancer Market

A number of equities analysts have commented on ILMN shares. Royal Bank of Canada decreased their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. Canaccord Genuity Group lowered their price objective on shares of Illumina from $115.00 to $92.00 and set a "hold" rating for the company in a research report on Tuesday. Barclays cut their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird cut their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Finally, Citigroup dropped their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th.

Get Our Latest Stock Report on ILMN

Illumina Stock Down 0.2 %

• Strategic Buy Lights Up This Biotech Stock: Time to Invest?

Shares of Illumina stock opened at $77.10 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina has a 1-year low of $68.70 and a 1-year high of $156.66. The business has a 50-day moving average of $81.11 and a 200-day moving average of $117.11. The company has a market capitalization of $12.20 billion, a PE ratio of -10.04, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

• Palantir Was Left Out of the S&P 500; It Still Looks Like a Buy

Hedge funds have recently made changes to their positions in the company. Bleakley Financial Group LLC acquired a new stake in Illumina during the 4th quarter valued at $751,000. Van ECK Associates Corp raised its position in Illumina by 17.5% during the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after buying an additional 22,718 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Illumina during the 4th quarter worth about $1,464,000. Allworth Financial LP grew its stake in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after acquiring an additional 6,263 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Illumina in the 4th quarter valued at about $448,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

• Five stocks we like better than Illumina
• Should You Invest in Penny Stocks?
• Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet
• What Are Dividend Achievers? An Introduction
• Coca-Cola Company Stock Can Bubble to New Highs This Year
• Best ESG Stocks: 11 Best Stocks for ESG Investing
• 3 Stocks Lifting 2025 Guidance Despite Market Jitters

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Illumina Right Now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here